Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema (RAPIDe-2)

Pharvaris

Status and phase

Invitation-only

Phase 3

Phase 2

Conditions

Hereditary Angioedema - Type 2

Hereditary Angioedema Types I and II

C1 Esterase Inhibitor, Deficiency of

Hereditary Angioedema with C1 Esterase Inhibitor Deficiency

C1 Esterase Inhibitor Deficiency

C1 Esterase Inhibitor [C1-INH] Deficiency

Hereditary Angioedema Type I

C1 Inhibitor Deficiency

Hereditary Angioedema Type II

Hereditary Angioedema - Type 1

Hereditary Angioedema Attack

Hereditary Angioedema

Treatments

Drug: deucrictibant selected dose

Study type

Interventional

Funder types

Industry

Identifiers

NCT05396105

2023-505766-28-00 (EU Trial (CTIS) Number)

PHA022121-C303

Details and patient eligibility

About

This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks, in participants with HAE type 1 or type 2 (HAE-1/2). The study will enroll patients from Study PHA022121-C201 (NCT04618211) and Study PHA022121-C306 (NCT06343779) who elect to participate in this extension study and meet the eligibility requirements.

Full description

Part A of the study will enroll adult participants from Study PHA022121-C201. The double-blind treatment assignment from Study PHA022121-C201 will be maintained.

Part B will include participants rolling over from Part A and additionally enroll participants from Study PHA022121-C201 who did not participate in Part A, and participants from Study PHA022121-C306 who elect to participate in this extension study and meet the eligibility requirements.

Enrollment

140 estimated patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Signed and dated informed consent form
Diagnosis of HAE type I or II
For participants from Study C201, received at least one dose of study drug (including the non-attack visit) in Study C201. For participants from Study C306, participant was randomized (and for adolescent participants 12 to <18 years received a dose of study drug in a non-attack state at Visit 1) and completed Study C306, with 2 attacks treated, or after closure of that study by the Sponsor.
In the opinion of the Investigator, the participant (and parent/caregiver for adolescent participants) is willing and able to comply with the protocol.

Key Exclusion Criteria:

Pregnancy or breast-feeding
Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study
Use of lanadelumab for long-term HAE prophylactic therapy within 12 weeks prior to enrollment in Part A.
For Part A: Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrolment.

For Part B: If a participant is receiving long-term prophylactic therapy with one of the following medications indicated for HAE: plasma-derived C1-INH, danazol at less than or equal to 200 mg/day, anti-fibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.
History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse
Participation in any other investigational drug study within defined period
Discontinued from parent study after enrollment for any study drug-related safety reason.
Use of concomitant medications that are potent CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, grapefruit) or potent CYP3A4 inducers (e.g., phenytoin, rifampicin, St. John's Wort).